Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Latest glucose-lowering drug use and glycaemic outcome trends in HK
A retrospective cross-sectional analysis of trends in glucose-lowering drug (GLD) use and glycaemic outcomes among Hong Kong’s 0.9 million adults with diabetes between 2002 and 2019 finds a levelling off in improvements since 2014.
Latest glucose-lowering drug use and glycaemic outcome trends in HK
30 Aug 2022RYGB in severe obesity leads to weight loss, hypertension remission
In patients with severe obesity, undergoing either laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (RYGB) resulted in weight loss, according to long-term follow-up of the SLEEVEPASS* trial. However, remission of hypertension was more likely in patients who underwent RYGB compared with LSG.
RYGB in severe obesity leads to weight loss, hypertension remission
29 Aug 2022Combined oral contraceptives and VTE: Which pill conveys the highest risk in young women?
Combined oral contraceptives (COCs) that contain gestodene confer a fivefold increased risk of venous thromboembolism (VTE) in young women as compared with those that contain levonorgestrel and the lowest doses of ethinylestradiol, as shown in a study.
Combined oral contraceptives and VTE: Which pill conveys the highest risk in young women?
29 Aug 2022Obese, postmenopausal women on proinflammatory diet at highest risk of breast cancer
A recent meta-analysis has confirmed the association of a proinflammatory diet with an increased risk of breast cancer, particularly among women who are obese, postmenopausal, and living in developing countries.
Obese, postmenopausal women on proinflammatory diet at highest risk of breast cancer
29 Aug 2022Add-on pembrolizumab–tocilizumab combo reduces hospitalization period in severe COVID-19
In the treatment of patients with severe COVID-19, adding the combination of pembrolizumab plus tocilizumab to standard of care (SOC) appears to result in higher and faster discharge from the hospital without sequelae, as shown in the proof-of-concept phase II COPERNICO trial.